FMR1 and fragile X syndrome: Two groups independently developed high-throughput drug screening assays to measure FMR1 reactivation in FXS-iPSC-derived neural cells, using high-content imaging [65] or time-resolved fluorescence resonance energy transfer (TR-FRET) [67].